Investors Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.

Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx®, designed to provide extended-release drug delivery, while safeguarding against common methods of abuse and tampering including crushing, chewing, heating and injecting.

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. While abuse of Xtampza ER is still possible, FDA has determined that the product has abuse-deterrent properties. The Xtampza ER label supports alternate administration options, including, sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube.

Stock Quote

COLL (Common Stock)
PriceChange% ChangeVolume
$9.81 - 0.212.10%61,977
Previous CloseToday's OpenIntraday HighIntraday Low
$10.02$10.02$10.06$9.63
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

More »
DateTitle 
04/20/17Collegium to Present at the 42nd Annual Deutsche Bank Healthcare ConferencePrinter Friendly Version
04/04/17Collegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and PolicyPrinter Friendly Version
04/03/17Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D PatientsPrinter Friendly Version

Upcoming Events

More »

There are currently no events scheduled.